The strongest preclinical evidence supports BPC-157 use for tendon and ligament repair, gut-lining integrity in NSAID-related damage, and inflammation reduction in musculoskeletal tissues
For more on oral versus injectable administration, see our next article, the BPC-157 Administration Guide
This deficiency is common, affecting approximately 6% of people under the age of 60 and 20% of people over the age of 60
Nausea affects approximately 28% of users at the 12mg dose, with diarrhea (24%), constipation (21%), and vomiting (17%) also common
Do NOT use the following: Sodium chloride (saline) BAC water: The salt content can destabilize peptides like Retatrutide, lower potency, and in some cases cause cloudiness or visible degradation